摘要
目的胞吞作用在多种疾病中都已证实与疾病进程有着紧密的关联,但关于胞吞在癌症中的作用的研究相对有限。本研究旨在探索胞吞相关基因在肝癌(HCC)中的角色及其与生存预后的关联。方法我们从TCGA和GEO数据库中下载了HCC的转录组表达谱和匹配的临床信息。通过“limma”R包进行差异分析以识别差异表达基因。采用LASSO Cox回归分析构建了胞吞相关的预后特征,并在GEO数据集上进行验证。结合TNM分期和其他临床变量,我们进一步建立了预后列线图。结果成功鉴定了33个与胞吞有关的差异表达基因,并进一步筛选出6个关键胞吞相关基因,包括ALDH2、C3、ANXA2、CD5L、IL33和HAVCR1。这些基因在HCC的生存中表现出显著的相关性(P<0.01)。通过多数据集的验证,预后特征显示出较好的准确性和稳定性。结合临床变量进行的深入分析证实,胞吞相关预后特征是HCC总体生存率的独立预测因子(P<0.01)。我们构建了一个胞吞相关的列线图。该列线图在整体样本中的1年、3年和5年生存预测的AUC值分别为70.7%、70.4%和70.1%,表现出较好的预测性能。结论本研究系统鉴定了胞吞相关预后基因并构建了HCC预后特征,该模型在预后评估中展现卓越准确性,为HCC治疗提供新思路,但仍需进一步研究验证。
Objective Efferocytosis is linked to a variety of disease progression,yet its role in cancer remains under-researched.This study aims at investigating the genes associated with efferocytosis in hepatocellular carcinoma(HCC)and to evaluate their significance in prognosis.Methods Transcriptomes and clinical data for HCC were sourced from TCGA and GEO databases.“Limma”R package was used for differential expression analysis.An efferocytosis-based prognostic signature was created with LASSO Cox regression analysis method,followed by a validation with GEO data.A prognostic nomogram was also developed by incorporating TNM stages and clinical factors.Results Thirty-three efferocytosis-related differentially expressed genes were identified.Within them,six key genes(i.e.,ALDH2,C3,ANXA2,CD5L,IL33,and HAVCR1)were significantly correlated with the survival of HCC patients(P<0.01).The signature built on these genes was accurate and stable after validation in different datasets,which may serve as an independent overall survival predictor for HCC(P<0.01).The AUCs of the nomogram for predicting the 1,3,and 5-year survival of HCC patients were 70.7%,70.4%,and 70.1%.respectively.Conclusion Key efferocytosis genes were identified in this study to build a prognostic signature of HCC with an high accuracy,which provide new insight in HCC treatment and warrant further validation.
作者
徐昀霏
姚向庆
罗梅娣
XU Yun-fei;YAO Xiang-qing;LUO Mei-di(Department of Hepatopancreatobiliary Surgery,the First Affiliated Hospital,Fujian Medical University,Fuzhou 350005,China;Department of Hepatopancreatobiliary Surgery,National Regional Medical Center,Binhai Campus of the First Affiliated Hospital,Fujian Medical University,Fuzhou 350212,China)
出处
《肝脏》
2024年第4期400-407,共8页
Chinese Hepatology
关键词
肝细胞癌
胞吞作用
预后特征
Hepatocellular carcinoma
Efferocytosis
Prognostic Signature
